DR REDDYS LABORATORIES LTD
DR REDDYS LABORATORIES LTD (RDY): 125 pipeline candidates. Updated within the last hour.
BioSniper Score
3-factor signal · derived from public data
N/A
D/E 0.46 · 0% dilution
Lead: Approved
125 candidates
N/A
N/A
A transparent, data-derived signal for DR REDDYS LABORATORIES LTDacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$11.0B
Cash
$172.0M
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (125 candidates)
| Drug | Phase |
|---|---|
| abiraterone | Approved |
| abiraterone | Approved |
| acetaminophen | Approved |
| acetaminophen | Approved |
| amlodipine | Approved |
| apixaban | Approved |
| aspirin | Approved |
| atomoxetine | Approved |
| atorvastatin | Approved |
| azacitidine | Approved |
Showing 10 of 125 candidates. Sign up for full pipeline.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
244
Total value held
$1.24B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 11,587,127 | $160.5M |
| royal bank of canada | 9,984,082 | $138.3M |
| morgan stanley | 9,371,594 | $129.8M |
| renaissance technologies llc | 7,859,728 | $108.9M |
| vanguard capital management llc | 6,201,822 | $85.9M |
| dimensional fund advisors lp | 5,323,248 | $73.7M |
| state street corp | 4,026,207 | $55.8M |
| bnp paribas financial markets | 3,183,971 | $44.1M |
| franklin resources inc | 2,856,094 | $39.6M |
| marshall wace, llp | 2,664,306 | $36.9M |
Showing top 10 of 244 institutional holders of DR REDDYS LABORATORIES LTD. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in DR REDDYS LABORATORIES LTD's pipeline?
DR REDDYS LABORATORIES LTD (RDY) has 125 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is DR REDDYS LABORATORIES LTD's lead drug candidate?
DR REDDYS LABORATORIES LTD's most advanced tracked candidate is abiraterone (Approved) for 1 INDICATIONS AND USAGE Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with Metastatic castration-resistant prostate cancer (CRPC) Metastatic high-risk castration-sensitive prostate cancer (CSPC) Abiraterone acetate tablet is a CYP17 inhibitor indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC). ( 1) metastatic high-risk castration-sensitive prostate cancer (CSPC.
What is DR REDDYS LABORATORIES LTD's market capitalization?
DR REDDYS LABORATORIES LTD's market capitalization is approximately $11.0B.
Who is the CEO of DR REDDYS LABORATORIES LTD?
Mr. Erez Israeli M.B.A. is the chief executive officer of DR REDDYS LABORATORIES LTD (RDY).
Get the full picture on DR REDDYS LABORATORIES LTD
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.